miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression

Experimental and Therapeutic Medicine

Volumn 7, Issue 6, 2014, Pages 1757-1761

  Shen, Zhi Yong ^a   Zhang, Zi Zhen ^a   Liu, Hua ^a   Zhao, En Hao ^a   Cao, Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastric cancer; Human epidermal growth factor receptor 2; MicroRNA; Proliferation

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 375; MONOCLONAL ANTIBODY; RENILLA LUCIFERIN 2 MONOOXYGENASE;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION ASSAY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MRNA EXPRESSION ASSAY; NUCLEOTIDE BINDING SITE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 84898408761     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1627     Document Type: Article

References (16)

1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ and Ezzati M; Comparative Risk Assessment collaborating group (Cancers): Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366: 178 4-1793, 2005.
2. Delaunoit T: Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res 3: 257-266, 2011.
3. Bang YJ: Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol 46: 637-648, 2012.
4. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
5. Park YS, Hwang HS, Park HJ, et al: Comprehensive analysis of HER2 expression and gene amplifcation in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43: 413-422, 2012.
6. Fassan M, Mastracci L, Grillo F, et al: Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 61: 769-776, 2012.
7. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJ: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29: 5761-5771, 2010.
8. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302, 2009.
9. Ueda T, Volinia S, Okumura H, Shimizu M, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 11: 136-146, 2010.
10. Avissar M, Christensen BC, Kelsey KT and Marsit CJ: MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 15: 2850-2855, 2009.
11. Mathé EA, Nguyen GH, Bowman ED, Zhao Y, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 15: 6192-6200, 2009.
12. Liu AM, Poon RT and Luk JM: MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 394: 623-627, 2010.
13. Ding L, Xu Y, Zhang W, Deng Y, et al: MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20: 784-793, 2010.
14. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, et al: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70: 2339-2349, 2010.
15. Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17: 3077-3079, 2010.
16. Rüschoff J, Hanna W, Bilous M, Hofmann M, et al: HER2 testing in gastric cancer: a practical approach. Mod Pathol 25: 637-650, 2012.